CClinicalTrials.gg
Not yet recruitingNCT07389915PRECABIDO2Updated Feb 5, 2026

A Convolutional Neural Network for Difficult Biliary Cannulation

An observational study in Difficult Biliary Cannulation, sponsored by University of La Laguna. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by University of La Laguna · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
600
Sex
All
01

Study summary

The main purpose of the study is to train a convolutional neural network (CNN) to predict difficult biliary canulation (DBC) following the European Society of Gastrointestinal Endoscopy Society (ESGE). Consecutive patients undergoing an endoscopic retrograde cholangiopancreatography (ERCP) will be included in the study. Several pictures of the second portion of the duodenum including the ampulla will be taken, along with several pictures of the radiological image. Pictures prospectively collected from the study PRECABIDO (NCT06591364), a multicenter study whith the purpose of evaluating the prevalence of difficult biliary cannulation and predictive factors for difficult cannulation and cannulation failure using ESGE criteria were also used for the training of the CNN.

We will also assess:

A validation of the CNN assessing the agreement between ESGE criteria and the CNN prediction.

To design a novel application based on the use of a convolutional neural network (CNN) to detect difficult biliary cannulation.

.

Read the detailed description

All consecutive patients who meet the inclusion criteria and none of the exclusion criteria will be offered participation in the study. They will be informed by one of the investigators from each center and will sign an informed consent form. A data collection sheet will be completed to record demographic data, the indication for the procedure, and technical variables.

The procedures will be performed by endoscopists with at least 200 ERCPs and more than 5 years of experience. All patients, except in cases of allergy, will receive 1 suppository of indomethacin or diclofenac before the procedure. In cases of allergy, pre-procedure hydration with Ringer's lactate will be administered if there is no contraindication (consider the protocol proposed by the ESGE: 3 mL/kg/hour during ERCP, 20 mL/kg as a bolus after ERCP, and 3 mL/kg/hour for 8 hours post-ERCP). The use of a pancreatic stent should be considered when indicated.

After the procedure, patients will remain hospitalized for at least 24 hours in the hospital. The patient's medical record will be reviewed 7 days after the procedure to check for any adverse effects, and a follow-up phone call will be made to detect any adverse effects.

Initially, a pilot study will be conducted with 600 patients, assessing based on the results-that is, the percentage of patients with difficult cannulation. At the beginning of the examination, at least three endoscopic images and three radiological images of the second portion of the duodenum will be captured for each patient. In patients undergoing endoscopic ultrasound (EUS), three additional images of the second portion of the duodenum at the level of the pancreatic head and common bile duct (CBD) will be obtained.

These images will be labeled as "CBD yes" or "CBD no" according to ESGE criteria, which will serve as the gold standard. Once labeled, the images will be used to train a convolutional neural network (CNN) capable of predicting, just before attempting biliary cannulation, whether it will be a CBD or not.

The prediction of the trained CNN will be able to be combined with the predictive model of difficult biliary cannulation obtaned from the study PRECABIDO NCT06591364 in order to improve the prediction.

02

Conditions studied

  • Difficult Biliary Cannulation

Keywords

  • ERCP
  • Difficult biliary cannulation
  • Convolutional neural network
  • CNN
03

In context

Lead sponsor

University of La Laguna is the lead sponsor of 16 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All consecutive patients who meet the inclusion criteria and none of the exclusion criteria will be offered participation in the study.

Inclusion criteria

  • Age >18 years
  • Signed informed consent
  • Patients indicated for ERCP

Exclusion criteria

Exclusion Criteria:

  • INR > 1.5
  • Platelets \< 50,000/mm³
  • Patients with a prior endoscopic sphincterotomy
  • Papilla of Vater not accessible via duodenoscope (gastric or duodenal stenosis due to neoplasm) or gastric surgery (Billroth II, Roux-en-Y)
  • Known pancreas divisum
  • Indication due to pancreatic duct pathology
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
600 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients undergoing ERCP

    Consecutive patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) will be included

    Procedure: Endoscopic retrograde cholangiopancreatography (ERCP)

Interventions

  • ProcedureEndoscopic retrograde cholangiopancreatography (ERCP)

    Patients with a clinical indication of Endoscopic retrograde cholangiopancreatography (ERCP) will be included in the study for malignant or benign conditions as in routine clinical practice. Endoscopic and radiological images of the second portion of the duodenum will be captured for each patient. In patients undergoing endoscopic ultrasound (EUS), additional images of the second portion of the duodenum at the level of the pancreatic head and common bile duct (CBD) will be obtained

06

What researchers measure

Primary outcomes

  1. To train a convolutional neural network to predict difficult biliary canulation

    To train a convolutional neural network to predict difficult biliary canulation following the European Society of Gastrointestinal Endoscopy Society (ESGE): Assessment of difficult biliary cannulation defined by ESGE criteria (\> 5 minutes duration until cannulation, \> 5 cannulation attempts, \> 1 passage of the guidewire into the main pancreatic duct). Based on these criteria pictures will be labelled as difficult biliary cannulation or not

    Time frame: 1 year

Secondary outcomes

  1. A validation of the CNN

    A validation of the CNN assessing the agreement between ESGE criteria and the CNN prediction

    Time frame: 1 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07389915
Lead sponsor
University of La Laguna
Responsible party
Manuel Hernandez-Guerra, MD (MD, PhD, University of La Laguna) — Principal investigator
First posted
Feb 5, 2026
Start date
Feb 1, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Feb 5, 2026

Study contacts

Antonio Z Gimeno García, MD, PhD
Contact
antozeben@gmail.com
34-922678039 ext. 34039

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion